These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

325 related articles for article (PubMed ID: 28699217)

  • 21. Safety of infliximab and other biologic agents in the inflammatory bowel diseases.
    Reddy JG; Loftus EV
    Gastroenterol Clin North Am; 2006 Dec; 35(4):837-55. PubMed ID: 17129816
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tuberculosis in Anti-Tumour Necrosis Factor-treated Inflammatory Bowel Disease Patients After the Implementation of Preventive Measures: Compliance With Recommendations and Safety of Retreatment.
    Carpio D; Jauregui-Amezaga A; de Francisco R; de Castro L; Barreiro-de Acosta M; Mendoza JL; Mañosa M; Ollero V; Castro B; González-Conde B; Hervías D; Sierra Ausin M; Sancho Del Val L; Botella-Mateu B; Martínez-Cadilla J; Calvo M; Chaparro M; Ginard D; Guerra I; Maroto N; Calvet X; Fernández-Salgado E; Gordillo J; Rojas Feria M;
    J Crohns Colitis; 2016 Oct; 10(10):1186-93. PubMed ID: 26802085
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Optimizing biologic therapies for inflammatory bowel disease (ulcerative colitis and Crohn's disease).
    Ferrante M; D'Haens G; Rutgeerts P; Vermeire S; Van Assche G
    Curr Gastroenterol Rep; 2009 Dec; 11(6):504-8. PubMed ID: 19903427
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Risk of infection and prevention in pediatric patients with IBD: ESPGHAN IBD Porto Group commentary.
    Veereman-Wauters G; de Ridder L; Veres G; Kolacek S; Fell J; Malmborg P; Koletzko S; Dias JA; Misak Z; Rahier JF; Escher JC;
    J Pediatr Gastroenterol Nutr; 2012 Jun; 54(6):830-7. PubMed ID: 22584748
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Optimal use and cost-effectiveness of biologic therapies in inflammatory bowel disease.
    Di Sabatino A; Liberato L; Marchetti M; Biancheri P; Corazza GR
    Intern Emerg Med; 2011 Oct; 6 Suppl 1():17-27. PubMed ID: 22009609
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Risk Factors for Medication Nonadherence to Self-Injectable Biologic Therapy in Adult Patients With Inflammatory Bowel Disease.
    Shah NB; Haydek J; Slaughter J; Ashton JR; Zuckerman AD; Wong R; Raffa F; Garrett A; Duley C; Annis K; Wagnon J; Gaines L; Dalal R; Scoville E; Beaulieu DB; Schwartz D; Horst SN
    Inflamm Bowel Dis; 2020 Jan; 26(2):314-320. PubMed ID: 31671188
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The use of biologic therapy in pregnancy: a gastroenterologist's perspective.
    Hassid B; Mahadevan U
    Curr Opin Rheumatol; 2014 May; 26(3):347-53. PubMed ID: 24625373
    [TBL] [Abstract][Full Text] [Related]  

  • 28. De-escalation of immunomodulator and biological therapy in inflammatory bowel disease.
    Chapman TP; Gomes CF; Louis E; Colombel JF; Satsangi J
    Lancet Gastroenterol Hepatol; 2020 Jan; 5(1):63-79. PubMed ID: 31818473
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Biologic therapy is associated with a mild decrease in the rate of hospitalizations in pediatric IBD.
    Berkovitch G; Cohen S; Lubetzky R; Singer D; Yerushalmy-Feler A
    BMC Pediatr; 2021 Feb; 21(1):63. PubMed ID: 33541320
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The risk of infections with biologic therapies for rheumatoid arthritis.
    Furst DE
    Semin Arthritis Rheum; 2010 Apr; 39(5):327-46. PubMed ID: 19117595
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Understanding the Cautions and Contraindications of Immunomodulator and Biologic Therapies for Use in Inflammatory Bowel Disease.
    Cohn HM; Dave M; Loftus EV
    Inflamm Bowel Dis; 2017 Aug; 23(8):1301-1315. PubMed ID: 28708806
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Significant risk and associated factors of active tuberculosis infection in Korean patients with inflammatory bowel disease using anti-TNF agents.
    Kim ES; Song GA; Cho KB; Park KS; Kim KO; Jang BI; Kim EY; Jeon SW; Lee HS; Yang CH; Lee YK; Lee DW; Kim SK; Kim TO; Lee J; Kim HW; Jee SR; Park SJ; Kim HJ
    World J Gastroenterol; 2015 Mar; 21(11):3308-16. PubMed ID: 25805938
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Optimizing the safety of biologic therapy for IBD.
    de Silva S; Devlin S; Panaccione R
    Nat Rev Gastroenterol Hepatol; 2010 Feb; 7(2):93-101. PubMed ID: 20134491
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Risk of infections associated with biological treatment in inflammatory bowel disease.
    Andersen NN; Jess T
    World J Gastroenterol; 2014 Nov; 20(43):16014-9. PubMed ID: 25473153
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Risk factors for opportunistic infections in patients with inflammatory bowel disease.
    Toruner M; Loftus EV; Harmsen WS; Zinsmeister AR; Orenstein R; Sandborn WJ; Colombel JF; Egan LJ
    Gastroenterology; 2008 Apr; 134(4):929-36. PubMed ID: 18294633
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The London position statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organisation: safety.
    Van Assche G; Lewis JD; Lichtenstein GR; Loftus EV; Ouyang Q; Panes J; Siegel CA; Sandborn WJ; Travis SP; Colombel JF
    Am J Gastroenterol; 2011 Sep; 106(9):1594-602; quiz 1593, 1603. PubMed ID: 21844919
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Risks and benefits of biologic therapy for inflammatory bowel diseases.
    D'Haens G
    Gut; 2007 May; 56(5):725-32. PubMed ID: 17440187
    [No Abstract]   [Full Text] [Related]  

  • 38. Safety of biologic therapy in rheumatoid arthritis.
    Woodrick RS; Ruderman EM
    Nat Rev Rheumatol; 2011 Oct; 7(11):639-52. PubMed ID: 21989284
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Current concepts about the treatment of inflammatory bowel disease, biological therapy].
    Bosques-Padilla FJ; Galindo-Marines SL; Yamamoto-Farusho JK
    Rev Gastroenterol Mex; 2008; 73(4):217-30. PubMed ID: 19666271
    [TBL] [Abstract][Full Text] [Related]  

  • 40. De-escalation of biological therapy in inflammatory bowel disease: Benefits and risks.
    Fredericks E; Watermeyer G
    S Afr Med J; 2019 Sep; 109(10):745-749. PubMed ID: 31635571
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.